Company intelligence / Profile preview
CAMP4 Therapeutics
Cambridge, Massachusetts, United Statescamp4tx.com ↗
- Ownership
- Public · CAMP
- Employees
- ~55
- Development stage
- Phase 1
01
Overview
The company’s lead candidate, CMP-CPS-001, is in a Phase 1 trial for urea cycle disorders with interim safety data showing favorable results in healthy volunteers. Preclinical data support the potential of their regulatory RNA-targeting approach to upregulate protein production in genetic diseases with insufficient protein levels. Additional programs are advancing toward IND-enabling studies.[6][8][9]
- Therapeutic areas
- NeurologyMetabolic Disorders
- Modalities
- Antisense oligonucleotides (ASOs)RNA-based therapeutics[2][8]
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $233.4M
- Total revenue
- $3.5M
- Enterprise value
- $115.4M
Beyond the preview
Go deeper on CAMP4 Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAMP4 Therapeutics.